Sustainability at Biocon

Biocon 1 Financial Highlights: FY22 Revenue FY22 +14% 8,397Cr FY 21 *7,398Cr Biosimilars +24% | Research Services +19% Generics -1% | Dilution Gain in Bicara of 30Cr vs 160Cr in FY21 Mark-to-market loss on investments of *28Cr; Forex Gain of 58Cr vs loss of 9Cr in FY21 * Core EBITDA* +18% 2,669Cr *2,270Cr % margin 32% 31% EBITDA +14% 2,183Cr *1,907Cr Gross R&D spend at *711Cr R&D spend in P&L *595Cr % margin Profit Before Tax +4% before Exceptional Items 26% 26% *1,094Cr *1,055Cr Exceptional Loss at *111Cr % margin 13% 14% Net Profit Before Exceptional Items % margin *722Cr 9% *744Cr 10% *Core EBITDA defined as EBITDA before forex, dilution gain in Bicara, R&D, mark-to-market loss on investments and licensing income Net Profit after exceptional items at *648Cr

View entire presentation